Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/174574
Title: | Cost-effectiveness of direct oral anticoagulants versus vitamin K antagonist in atrial fibrillation: A study protocol using Real-World Data from Catalonia (FantasTIC Study) |
Author: | Hernández Rojas, Zojaina Dalmau Llorca, Maria Rosa Aguilar Martín, Carina Gonçalves, Alessandra Queiroga Casajuana, Marc Fernández Sáez, José Rodríguez Cumplido, Dolores Forcadell Drago, Emma Carrasco Querol, Noèlia Pepió i Vilaubí, Josep M. Alegret, Josep M. |
Keywords: | Cost de l'assistència sanitària Catalunya Assaigs clínics Anticoagulants (Medicina) Vitamines K Cost of medical care Catalonia Clinical trials Anticoagulants (Medicine) Vitamin K |
Issue Date: | 4-Sep-2020 |
Publisher: | Ovid Technologies (Wolters Kluwer Health) |
Abstract: | Background: Anticoagulant therapy is used for stroke prevention and proved to be effective and safe in the long term. The study aims to analyse the cost-effectiveness relationship of using of direct-acting oral anticoagulants vs vitamin K antagonists to prevent ischaemic stroke in patients with nonvalvular atrial fibrillation, including all the active ingredients marketed in Spain, prescribed for 2 years in the Primary Care service of the Institut Català de la Salut. Methods: Population-based cohort study, in which the cost of the 2 treatment groups will be evaluated. Direct costs (pharmacy, primary care, emergency and hospitalization) and indirect costs (lost productivity) will be included from a social perspective. Effectiveness (assessed as the occurrence of a health event, the 1 of primary interest being stroke) will be determined, with a 2-year time horizon and a 3% discount rate. The average cost of the 2 groups of drugs will be compared using a regression model to determine the factors with the greatest influence on determining costs. We will carry out a univariate ('one-way') deterministic sensitivity analysis. Discussion: We hope to provide relevant information about direct and indirect costs of oral anticoagulants, which, together with aspects of effectiveness and safety, could help shape the consensual decision-making of evaluating bodies. |
Note: | Reproducció del document publicat a: https://doi.org/10.1097/MD.0000000000022054 |
It is part of: | Medicine, 2020, vol. 99 (36), num. e22054 |
URI: | http://hdl.handle.net/2445/174574 |
Related resource: | https://doi.org/10.1097/MD.0000000000022054 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Cost_effectiveness_of_direct_oral_anticoagulants.79.pdf | 281.63 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License